PubMed , Clinical Gastroenterology and Hepatology , vol
In STEP 4 (Rubino et al., JAMA 2021), all patients from week 0 to week 20 reached the full 2.4 mg weekly dose and lost an average of 10.6% of body weight in those 20 weeks
In contrast, heterozygous individuals demonstrated later onset (mean: 29.8 years), milder C1-INH deficiency (52.9%), and a comparable attack rate (25.9/year)
The number of evaluable completers was 5 for 0.2 mg SAR425899 and 1 for 0.12 mg SAR425899
peptide community, author of five longevity-focused books and co-founder of BioLongevity Labs, an e-commerce seller of peptides and bioregulators
Real-time adjustment instead of wait and see. If you hit a plateau or experience side effects, we adjust your dose, nutrition, or timing we dont leave you to figure it out alone